EHC Stock Surges 21% With A 7-day Winning Spree On Strong Q4 Earnings Beat
Encompass Health (EHC) – a provider of inpatient rehabilitation, home health, and hospice services – hit a 7-day winning streak, with cumulative gains over this period amounting to 21%. The company’s market cap has surged by about $2.0 Bil over the last 7 days and currently stands at $11 Bil.
The stock has YTD (year-to-date) return of 7.1% compared to 1.4% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Strong Q4 2025 Earnings & Positive 2026 Guidance
- Adjusted EPS of $1.46 Beat Estimates by $0.17
- Raised Full-Year 2026 EPS Guidance
- Impact: Significant Price Surge, Increased Trading Volume
[2] Favorable Analyst Ratings Post-Earnings
- Truist Securities Reiterated ‘Buy’ Rating
- Barclays Raised Price Target to $150
- Impact: Sustained Positive Stock Momentum, Reinforced Investor Confidence
Opportunity or Trap?
Below is our take on valuation.
There is a near-equal mix of good and bad in EHC stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell EHC).
But here is the real interesting point.
You are reading about this 21% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for EHC stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | EHC | S&P 500 |
|---|---|---|
| 1D | 4.1% | -0.0% |
| 7D (Current Streak) | 20.9% | -0.5% |
| 1M (21D) | 10.4% | -0.5% |
| 3M (63D) | -1.4% | 1.6% |
| YTD 2026 | 7.1% | 1.4% |
| 2025 | 15.7% | 16.4% |
| 2024 | 39.2% | 23.3% |
| 2023 | 12.6% | 24.2% |
However, big gains can follow sharp reversals – but how has EHC behaved after prior drops? See EHC Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 101 S&P constituents with 3 days or more of consecutive gains and 52 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 40 |
| 4D | 56 | 5 |
| 5D | 9 | 3 |
| 6D | 3 | 1 |
| 7D or more | 10 | 3 |
| Total >=3 D | 101 | 52 |
Key Financials for Encompass Health (EHC)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $4.8 Bil | $5.4 Bil |
| Operating Income | $731.8 Mil | $864.5 Mil |
| Net Income | $352.0 Mil | $455.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $1.5 Bil | $1.5 Bil |
| Operating Income | $259.1 Mil | $243.6 Mil |
| Net Income | $142.1 Mil | $126.5 Mil |
While EHC stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.